In early CNS drug development, false negatives can stop promising compounds too soon. A pharmacological signal may be present, but remain undetected because the selected biomarkers are not sensitive enough or are not aligned with the compound’s mechanism of action.
Building on more than 25 years of experience with NeuroCart®, NeuroKit® makes sensitive CNS pharmacodynamic assessments available for use in broader clinical research settings. By enabling functional CNS effects to be measured more consistently, including at trained sites beyond CHDR in the Netherlands, it creates new opportunities to incorporate these assessments into early studies and multicentre patient research.
Below, we outline six ways to reduce the risk of false negatives in CNS development and show how NeuroKit can support each step.
1. Align Assessments with the Mechanism of Action
A common reason for false-negative findings is the use of endpoints that are not well matched to the biology of the compound being studied.
Different CNS mechanisms affect different functional domains. A compound targeting alertness may influence attention and vigilance, while a cognitive enhancer may primarily affect memory or information processing. If the wrong endpoints are selected, meaningful pharmacological effects can be missed.
NeuroKit supports mechanism-aligned endpoint selection by providing assessments across multiple CNS domains, including cognition, psychomotor performance, neurophysiology, and subjective effects. Selecting measures that are relevant to the expected pharmacology increases the likelihood of detecting genuine CNS activity early in development.
2. Measure Functional CNS Effects
Early development programmes are often designed primarily around pharmacokinetics and safety. While these are essential, they do not always show whether a compound produces measurable effects on CNS function.
NeuroKit complements these approaches by assessing functional CNS outcomes directly. Rather than focusing solely on whether a target is engaged, researchers can evaluate whether engagement translates into measurable effects on cognition, alertness, motor function, or other relevant domains.
This additional layer of evidence can provide a clearer picture of pharmacology and reduce uncertainty when making early development decisions.
3. Detect Subtle Pharmacodynamic Signals Early
Many CNS compounds produce measurable pharmacodynamic effects before clinical readouts become apparent. These early signals are often small and can be difficult to distinguish from normal variability.
NeuroKit incorporates sensitive assessments designed to detect subtle changes in CNS function. Even modest effects can provide important evidence that a compound is engaging relevant neural systems and producing expected pharmacological responses.
Detecting these signals early can support dose selection, study design decisions, and progression to later development stages.
4. Strengthen Confidence Through Exposure-Response Relationships
Detecting a signal is only the first step. Researchers must also determine whether the observed effects are genuinely related to the investigational drug.
Sensitive pharmacodynamic assessments can help show whether functional CNS effects are related to drug exposure. Because NeuroKit assessments can be performed sequentially during a study visit, researchers can evaluate whether CNS effects change over time in relation to the pharmacokinetic profile of the compound.
When effects emerge as concentrations rise, peak near maximal exposure, and diminish as concentrations decline, confidence increases that the changes reflect genuine pharmacology rather than random variability.
This is particularly valuable in early development, where decisions often depend on relatively small datasets. Demonstrating that CNS effects follow drug exposure can support dose selection and further clinical development decisions.
5. Build Evidence Across Multiple Functional Domains
The CNS is complex, and pharmacological effects rarely appear in a single endpoint alone. Evaluating multiple complementary measures can provide a more reliable picture of a compound's activity.
NeuroKit enables the collection of data across several functional domains, allowing researchers to evaluate patterns of effects rather than isolated findings. When multiple assessments demonstrate changes that are consistent with a compound's mechanism of action, confidence in the underlying signal increases.
This integrated approach can help distinguish true pharmacological activity from noise and reduce the risk of overlooking meaningful effects.
6. Enable Consistent CNS Assessments Across Research Sites
Variability in assessment procedures can obscure drug effects and contribute to false-negative outcomes. Historically, sensitive CNS pharmacodynamic testing has often been concentrated within specialised centres, limiting broader adoption.
Because NeuroKit has been validated for use outside CHDR, it enables standardised CNS assessments to be performed by trained personnel at other clinical research sites. This expands access to sensitive pharmacodynamic measurements while maintaining methodological consistency.
The ability to deploy the same validated assessments across multiple centres may be particularly valuable as CNS biomarkers and pharmacodynamic endpoints are increasingly incorporated into multicentre patient studies.
Better Signal Detection Leads to Better Decisions
In early CNS development, missed pharmacological signals can lead to premature stop decisions. Sensitive, mechanism-aligned assessments help reduce that risk.
NeuroKit brings these assessments together in a validated platform, supporting functional CNS measurement, early pharmacodynamic signal detection, exposure-response evaluation, and consistent use across research sites.
For CNS compounds, better signal detection means better-informed development decisions and a lower risk of losing promising therapies too early.
